Johnson & Johnson (NYSE:JNJ) is Essex Savings Bank’s 4th largest position

0

Essex Savings Bank increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) shares by 1.4% in the first quarter, HoldingsChannel reports. The fund held 75,710 shares of the company after buying an additional 1,077 shares during the quarter. Johnson & Johnson represents 4.4% of Essex Savings Bank’s portfolio, making it its 4th largest position. Essex Savings Bank’s holdings in Johnson & Johnson were worth $13,418,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Excalibur Management Corp increased its holdings of Johnson & Johnson shares 0.3% in the first quarter. Excalibur Management Corp now owns 40,212 shares of the company worth $7,127,000 after buying 113 more shares in the last quarter. Capital Investment Advisory Services LLC increased its holdings of Johnson & Johnson stock by 3.5% in the first quarter. Capital Investment Advisory Services LLC now owns 52,456 shares of the company worth $9,297,000 after purchasing an additional 1,752 shares in the last quarter. Verity & Verity LLC increased its equity stake in Johnson & Johnson by 4.8% during the first quarter. Verity & Verity LLC now owns 71,062 shares of the company worth $12,594,000 after purchasing 3,278 additional shares in the last quarter. Regent Peak Wealth Advisors LLC increased its holdings of Johnson & Johnson shares by 2.6% in the first quarter. Regent Peak Wealth Advisors LLC now owns 18,390 shares of the company worth $3,259,000 after purchasing an additional 460 shares in the last quarter. Finally, Calamos Wealth Management LLC increased its holding in Johnson & Johnson shares by 7.5% during the first quarter. Calamos Wealth Management LLC now owns 22,290 shares of the company worth $3,950,000 after purchasing an additional 1,557 shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Johnson & Johnson Stock up 0.2%

NYSE JNJ shares opened at $174.52 on Monday. The company’s 50-day simple moving average is $175.95 and its 200-day simple moving average is $174.46. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a market capitalization of $459.23 billion, a price-to-earnings ratio of 25.40, a growth price-to-earnings ratio of 3.28 and a beta of 0.63. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company posted revenue of $24.02 billion for the quarter, versus analyst estimates of $23.85 billion. In the same quarter last year, the company earned earnings per share of $2.48. The company’s revenue for the quarter increased by 3.0% compared to the same quarter last year. Stock analysts predict Johnson & Johnson will post EPS of 10.05 for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a yield of 2.59%. Johnson & Johnson’s payout ratio is currently 65.79%.

Insider buying and selling

Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The disclosure of this sale can be found here. 0.35% of the shares are currently held by insiders of the company.

Wall Street analysts predict growth

Several research analysts have recently published reports on JNJ shares. SVB Leerink slashed its target price on Johnson & Johnson shares from $200.00 to $194.00 in a Wednesday July 20 report. Daiwa Capital Markets began covering Johnson & Johnson shares in a Wednesday, June 22 report. They set an “outperform” rating for the company. Citigroup slashed its price target on Johnson & Johnson shares from $205.00 to $201.00 in a report Wednesday, July 20. Raymond James raised his price target on Johnson & Johnson shares from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 research report. Finally, StockNews.com upgraded Johnson & Johnson shares from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Four equity research analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a high buy rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $189.89.

About Johnson & Johnson

(Get an assessment)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

Comments are closed.